Novo Nordisk is facing an unprecedented crisis of confidence as the tumble in its valuations reached extremely fearful levels ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.

Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver ...

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

Novo Nordisk A/S’s blockbuster weight-loss drug Wegovy received Food and Drug Administration approval to treat a serious form ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

Trump’s push for price cuts and tariffs weighs on ‘obesity franchises’, which have missed out on equity market’s rise ...

A closer look at today's Trending Tickers - the stocks making the biggest moves worldwide - including Eli Lilly (LLY), Novo ...